Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Abeona Therapeutics Inc (NASDAQ: ABEO) closed at $4.73 up 3.96% from its previous closing price of $4.55. In other words, the price has increased by $3.96 from its previous closing price. On the day, 1.14 million shares were traded. ABEO stock price reached its highest trading level at $4.779 during the session, while it also had its lowest trading level at $4.53.
Ratios:
For a deeper understanding of Abeona Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.53 and its Current Ratio is at 9.74. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.09.
On March 05, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $16.
On July 03, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $15.H.C. Wainwright initiated its Buy rating on July 03, 2024, with a $15 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 13 ’25 when Alvino Mark sold 15,000 shares for $4.74 per share. The transaction valued at 71,168 led to the insider holds 62,252 shares of the business.
Alvino Mark bought 15,000 shares of ABEO for $71,168 on Nov 13 ’25. On Oct 16 ’25, another insider, Seshadri Vishwas, who serves as the Chief Executive Officer of the company, sold 249 shares for $5.49 each. As a result, the insider received 1,366 and left with 1,189,818 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABEO now has a Market Capitalization of 256325136 and an Enterprise Value of 73315136. As of this moment, Abeona’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.06. For the stock, the TTM Price-to-Sale (P/S) ratio is 640.81 while its Price-to-Book (P/B) ratio in mrq is 1.45. Its current Enterprise Value per Revenue stands at 183.288 whereas that against EBITDA is -0.905.
Stock Price History:
The Beta on a monthly basis for ABEO is 1.13, which has changed by -0.24418604 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, ABEO has reached a high of $7.54, while it has fallen to a 52-week low of $3.93. The 50-Day Moving Average of the stock is -5.51%, while the 200-Day Moving Average is calculated to be -16.61%.
Shares Statistics:
For the past three months, ABEO has traded an average of 1.63M shares per day and 1628140 over the past ten days. A total of 52.40M shares are outstanding, with a floating share count of 49.19M. Insiders hold about 9.22% of the company’s shares, while institutions hold 62.41% stake in the company. Shares short for ABEO as of 1763078400 were 13589078 with a Short Ratio of 8.32, compared to 1760486400 on 9188242. Therefore, it implies a Short% of Shares Outstanding of 13589078 and a Short% of Float of 26.740000000000002.
Earnings Estimates
The market rating for Abeona Therapeutics Inc (ABEO) is a result of the insights provided by 3.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.05 and low estimates of -$0.15.
Analysts are recommending an EPS of between $1.33 and -$1.6 for the fiscal current year, implying an average EPS of -$0.14. EPS for the following year is -$0.07, with 3.0 analysts recommending between $0.2 and -$0.36.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $18.67M. There is a high estimate of $24.9M for the next quarter, whereas the lowest estimate is $9.6M.
Based on 7 analysts’ estimates, the company’s revenue will be $112.09M in the next fiscal year. The high estimate is $140.3M and the low estimate is $79.84M.
